Cover Image
市場調查報告書

前列腺癌症治療藥的全球市場 (到2020年)

Global Prostate Cancer Therapeutics Market to 2020

出版商 iGate Research Pvt Ltd 商品編碼 360456
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌症治療藥的全球市場 (到2020年) Global Prostate Cancer Therapeutics Market to 2020
出版日期: 2015年05月11日 內容資訊: 英文 76 Pages
簡介

隨著全球各國人口增加和高齡化發展,前列腺癌症正成為醫療相關人員的最大、最優先的對象事項。新藥開發、在基因學&蛋白質體學領域的技術進步也對市場成長有貢獻。另一方面,藥物價格高和臨床實驗的成功率低,治療藥的副作用等也妨礙市場成長。

本報告提供全球前列腺癌症治療藥的市場相關分析,疾病概要和流行病學的情形,整體市場趨勢的變化及預測 (過去4年、今後6年份),各治療法 (治療藥的各類別)的詳細趨勢,新藥的開發、臨床實驗情形,市場成長要素和今後的課題等調查評估。

第1章 摘要整理

第2章 全球前列腺癌症治療藥的市場

第3章 全球的前列腺癌症發病數量

第4章 前列腺癌症治療藥的市場佔有率與其預測 (總計10年份)

  • 各治療法的市場佔有率
  • 各藥物的市場佔有率

第5章 前列腺治療的市場規模與其預測:各治療法 (總計10年份)

  • 荷爾蒙療法
  • 化療
  • 免疫療法
  • 標靶治療

第6章 荷爾蒙療法藥的銷售額與其預測 (到2020年)

  • LHRH (促性腺激素放出荷爾蒙) 拮抗劑
    • Zytiga
    • Gonax/Firmagon
  • LHRH類似體
    • Lupron
    • Zoladex
    • Decapeptyl
    • Eligard
    • Vantas
    • Leuplin
  • 抗雄激素劑
    • Casodex
    • Xtandi/MDV3100
    • Xtandi US/MDV3100

第7章 化療劑的銷售額與其預測 (到2020年)

  • Taxotere
  • Jevtana

第8章 免疫療法藥的市場

  • Provenge

第9章 標靶治療藥的市場

  • Xofigo/Alpharadin

第10章 推動市場要素

  • 創新的醫藥品的市場促進
  • 腫瘤治療的領域的技術進步
  • 在基因學、蛋白質體學領域的技術開發

第11章 市場課題

  • 前列腺癌症治療藥的價格高
  • 治療的副作用
  • 腫瘤治療藥相關臨床實驗的成功率低

圖表一覽

目錄

Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cancer drugs, low success rate of clinical trials and side effects of treatments among others.

Global Prostate Cancer - Key Therapies Analysis: The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. Chemotherapy was the second leading therapy for prostate cancer in 2014. However, growth in the targeted therapy is predicted to push chemotherapy back at the third position, while immunotherapy for prostate cancer stands at the last position in the prostate cancer therapeutics market.

Prostate Cancer Drugs Analysis: Zytiga leads the prostate cancer drugs market in 2014. Zytiga is facing stiff competition from Xtandi drugs which is expected to replace Zytiga as the leading prostate cancer drugs. In prostate cancer drugs market, Leuplin and Zoladex stands at the third and fourth position in 2014. The market share of both Leuplin and Zoladex is likely to plunge during the forecasting period. Lupron is standing at the fifth position. Bayer's targeted therapy drugs Xofigo is also rapidly catching up the market due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.

iGATE RESEARCH report titled Global Prostate Cancer Therapeutics Market to 2020 is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market.

The 4 Prostate Cancer Therapy Market covered in the report are as follows:

  • Hormonal Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

The above 4 Therapy has been further analyzed in terms of drugs sales and forecast (2011 - 2020):

1. Global Prostate Cancer - Hormonal Therapy Drugs Market

  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists - Zytiga, Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Leuplin
  • Anti-Androgens - Casodex, Xtandi or MDV3100, Xtandi US or MDV3100

2. Global Prostate Cancer - Chemotherapy Drugs Market

  • Taxotere
  • Jevtana

3. Global Prostate Cancer - Immunotherapy Drugs Market

  • Provenge

4. Global Prostate Cancer - Targeted Therapy Drugs Market

  • Xofigo or Alpharadin

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table of Contents

1. EXECUTIVE SUMMARY

2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET

3. GLOBAL PROSTATE CANCER INCIDENCE

4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE & FORECAST (2011 - 2020)

  • 4.1 Global Prostate Cancer - Therapy Market Share
  • 4.2 Global Prostate Cancer - Drugs Market Share

5. GLOBAL PROSTATE CANCER THERAPY MARKET & FORECAST (2011 - 2020)

  • 5.1 Global Prostate Cancer Hormonal Therapy Market & Forecast
  • 5.2 Global Prostate Cancer Chemotherapy Market & Forecast
  • 5.3 Global Prostate Cancer Immunotherapy Market & Forecast
  • 5.4 Global Prostate Cancer Targeted Therapy Market & Forecast

6. GLOBAL PROSTATE CANCER - HORMONAL THERAPY DRUGS SALES & FORECAST TO 2020

  • 6.1 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    • 6.1.1 Zytiga
    • 6.1.2 Gonax/ Firmagon
  • 6.2 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
    • 6.2.1 Lupron
    • 6.2.2 Zoladex
    • 6.2.3 Decapeptyl
    • 6.2.4 Eligard
    • 6.2.5 Vantas
    • 6.2.6 Leuplin
  • 6.3 Anti-Androgens
    • 6.3.1 Casodex
    • 6.3.2 Xtandi or MDV3100
    • 6.3.3 Xtandi US or MDV3100

7. GLOBAL PROSTATE CANCER - CHEMOTHERAPY DRUGS MARKET

  • 7.1 Taxotere
  • 7.2 Jevtana

8. GLOBAL PROSTATE CANCER - IMMUNOTHERAPY DRUGS MARKET

  • 8.1 Provenge

9. GLOBAL PROSTATE CANCER - TARGETED THERAPY DRUGS MARKET

  • 9.1 Xofigo or Alpharadin

10. GLOBAL PROSTATE CANCER MARKET - DRIVING FACTORS

  • 10.1 Innovative Drugs Driving the Market
  • 10.2 Advancement in Oncology Therapeutic Area
  • 10.3 Developments in Genomics & Proteomics

11. GLOBAL PROSTATE CANCER MARKET - CHALLENGES

  • 11.1 High Cost of Prostate Cancer Drugs
  • 11.2 Adverse Events of Treatment
  • 11.3 Low Success Rate in Clinical Testing For Oncology Drugs

LIST OF FIGURES:

  • Figure 2-1: Global - Prostate Cancer Therapeutics Market (Million US$), 2010 - 2014
  • Figure 2-2: Global - Forecast for Prostate Cancer Therapeutics Market (Million US$), 2015 - 2020
  • Figure 3-1: Global - Prostate Cancer Incidence (Number), 2007 - 2014
  • Figure 3-2: Global - Forecast for Prostate Cancer Incidence (Number), 2015 - 2020
  • Figure 5-1: Global Prostate Cancer - Hormonal Therapy Market (Million US$), 2011 - 2014
  • Figure 5-2: Global Prostate Cancer - Forecast for Hormonal Therapy Market (Million US$), 2015 - 2020
  • Figure 5-3: Global Prostate Cancer - Chemotherapy Market (Million US$), 2011 - 2014
  • Figure 5-4: Global Prostate Cancer - Forecast for Chemotherapy Market (Million US$), 2015 - 2020
  • Figure 5-5: Global Prostate Cancer - Immunotherapy Market (Million US$), 2011 - 2014
  • Figure 5-6: Global Prostate Cancer - Forecast for Immunotherapy Market (Million US$), 2015 - 2020
  • Figure 5-7: Global Prostate Cancer - Targeted Therapy Market (Million US$), 2013 - 2014
  • Figure 5-8: Global Prostate Cancer - Forecast for Targeted Therapy Market (Million US$), 2015 - 2020
  • Figure 6-1: Global - Zytiga Drugs Sales (Million US$), 2011 - 2014
  • Figure 6-2: Global - Forecast for Zytiga Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-3: Global - Gonax/ Firmagon Drugs Sales (Million US$), 2012 - 2014
  • Figure 6-4: Global - Forecast for Gonax Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-5: Global - Lupron Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-6: Global - Forecast for Lupron Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-7: Global - Zoladex Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-8: Global - Forecast for Zoladex Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-9: Global - Decapeptyl Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-10: Global - Forecast for Decapeptyl Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-11: Global - Eligard Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-12: Global - Forecast for Eligard Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-13: Global - Vantas Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-14: Global - Forecast for Vantas Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-15: Global - Leuplin Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-16: Global - Forecast for Leuplin Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-17: Global - Casodex Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-18: Global - Forecast for Casodex Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-19: Global - Xtandi or MDV3100 Drugs Sales (Million US$), 2012 - 2014
  • Figure 6-20: Global - Forecast for Xtandi or MDV3100 Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-21: Global - Xtandi US or MDV3100 Drugs Sales (Million US$), 2012 - 2014
  • Figure 6-22: Global - Forecast for Xtandi US or MDV3100 Drugs Sales (Million US$), 2015 - 2020
  • Figure 7-1: Global - Taxotere Drugs Sales (Million US$), 2011 - 2014
  • Figure 7-2: Global - Forecast for Taxotere Drugs Sales (Million US$), 2015 - 2020
  • Figure 7-3: Global - Jevtana Drugs Sales (Million US$), 2010 - 2014
  • Figure 7-4: Global - Forecast for Jevtana Drugs Sales (Million US$), 2015 - 2020
  • Figure 8-1: Global - Provenge Drugs Sales (Million US$), 2011 - 2014
  • Figure 8-2: Global - Forecast for Provenge Drugs Sales (Million US$), 2015 - 2020
  • Figure 9-1: Global - Xofigo or Alpharadin Drugs Sales (Million US$), 2013 - 2014
  • Figure 9-2: Global - Forecast for Xofigo or Alpharadin Drugs Sales (Million US$), 2015 - 2020
  • Figure 11-1: Therapeutic Categories - Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 - 2010

LIST OF TABLES:

  • Table 4-1: Global - Prostate Cancer Therapy Market Share (Percent), 2011 - 2014
  • Table 4-2: Global - Forecast for Prostate Cancer Therapy Market Share (Percent), 2015 - 2020
  • Table 4-3: Global - Prostate Cancer Drugs Market Share (Percent), 2011 - 2014
  • Table 4-4: Global - Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 - 2020
Back to Top